For the Inventor, By the Inventor

Enter assignee name

High Point, NC, United States of America

Transtech Pharma, Inc.

USPTO Granted Patents = 49

% Expired Patents = 61.2

CIPO Patents = 2

EPO Patents = 11

Forward Citations = 757

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Adnan M M Mjalli (34 out of 74 patents)

Robert Carl Andrews (22 out of 53 patents)

Dharma Rao Polisetti (13 out of 53 patents)

4. Ramesh Gopalaswamy (11 out of 12 patents)

5. Christopher Behme (10 out of 12 patents)

6. Stephen Thomas Davis (10 out of 18 patents)

7. Mustafa Guzel (9 out of 34 patents)

8. Thomas Scott Yokum (9 out of 14 patents)

9. Kalpathy Chidambareswaran Santhosh (9 out of 19 patents)

10. Anitha Hari (8 out of 10 patents)

11. Muralidhar Bondlela (7 out of 10 patents)

12. Ghassan Qabaja (7 out of 7 patents)

13. Robert Rothlein (7 out of 7 patents)

14. Govindan Subramanian (7 out of 24 patents)

15. Jeff Jiqun Zhu (7 out of 20 patents)

Core Competencies:

Phenyl-Heteroaryl Derivatives

RAGE Fusion Proteins

Oxadiazoanthracene Compounds

GLP-1 Receptor Ligands

Substituted Imidazole Derivatives

Benzazole Derivatives

Benzamide Glucokinase Activators

N-Heteroaryl Indole Carboxamides

Azole Derivatives

Benzimidazole Derivatives

Heteroaryl-Fused Nitrogen Heterocycles

Carboxamide Derivatives

49 patents: Sort by Forward Citations

1. 9045461 - Phenyl-heteroaryl derivatives and methods of use thereof (2015-06-02),

2. 9034341 - Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions (2015-05-19),

3. 8987295 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof (2015-03-24),

4. 8933222 - Oxadiazoanthracene compounds for the treatment of diabetes (2015-01-13),

5. 8877192 - Rage fusion proteins and methods of use (2014-11-04),

6. 8741900 - Phenyl-heteroaryl derivatives and methods of use thereof (2014-06-03),

7. 8718994 - Ligands for the GLP-1 receptor and methods for discovery thereof (2014-05-06),

8. 8703766 - Oxadiazoanthracene compounds for the treatment of diabetes (2014-04-22),

9. 8580833 - Substituted imidazole derivatives and methods of use thereof (2013-11-12),

10. 8524708 - Oxadiazoanthracene compounds for the treatment of diabetes (2013-09-03),

11. 8431575 - Phenyl-heteroaryl derivatives and methods of use thereof (2013-04-30),

12. 8404731 - Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors (2013-03-26),

13. 8383644 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof (2013-02-26),

14. 8377983 - Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors (2013-02-19),

15. 8372988 - Crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine (2013-02-12),

TransTech Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for the treatment of diseases such as cancer, diabetes, and neurodegenerative disorders. With a strong commitment to innovation, TransTech Pharma aims to improve patient outcomes through breakthrough drug discovery and development. For more information, please visit their website.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

49 Patents

#4 in High Point, NC

#176 in North Carolina

#7,133 in US

#14,256 in the World

High Point, NC, United States of America

Transtech Pharma, Inc.

Forward Citations = 757

67 inventors:

Adnan M M Mjalli (34 out of 74 patents)

Robert Carl Andrews (22 out of 53 patents)

Dharma Rao Polisetti (13 out of 53 patents)

4. Ramesh Gopalaswamy (11 out of 12 patents)

5. Christopher Behme (10 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…